Flavonoid supplement
Apigenin
Apigenin taken by mouth was poorly absorbed in a 2022 human study, with urinary metabolites equal to 0.5% of intake; the app lists 30% bioavailability.1
Apigenin after one dose: 50% at ~12 h, 25% at 24 h, 12.5% at 36 h.
Drawn from the half-life in the app's model, ~12 h. The model's figures
- Compound
- Apigenin
- Symbol
- API
- Family
- Supplements
- Parts
- 12
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Apigenin is a plant flavone that Viola and colleagues isolated from an aqueous extract of the dried flower heads of Matricaria recutita (chamomile) in a study published in Planta Medica in 1995.2 A 2019 review in BioMed Research International describes chamomile tea as "extremely rich in apigenin".3 The app lists apigenin as a flavonoid supplement taken by mouth at 50–100 mg/day, and describes it as a chamomile-derived flavonoid used in a sleep stack with magnesium L-threonate and L-theanine. The app grades the evidence for apigenin as emerging.
The human work read for this compound comprises a single-intake absorption study in healthy men, a two-week trial of a three-ingredient evening product, a chamomile extract trial in insomnia and a parsley-feeding trial.4,5,6,7 No placebo-controlled trial of apigenin alone for sleep was identified in the PubMed and ClinicalTrials.gov queries run for this compound.
How it works
Sources in this part
The app's notes describe apigenin as a GABA-A receptor modulator that lowers cortisol at night. The evidence read on receptors comes from a 1995 study of receptor binding assays and behavior tests in mice, not from people.2 Viola and colleagues, working at the Instituto de Biología Celular, Facultad de Medicina, Buenos Aires, reported that "Apigenin competitively inhibited the binding of flunitrazepam with a Ki of 4 microM".2 The same record says apigenin "had no effect on muscarinic receptors, alpha 1-adrenoceptors, and on the binding of muscimol to GABAA receptors".2 In mice, "a 10-fold increase in dosage produced a mild sedative effect since a 26% reduction in ambulatory locomotor activity and a 35% decrement in hole-board parameters were evident".2 The authors conclude that apigenin "is a ligand for the central benzodiazepine receptors exerting anxiolytic and slight sedative effects but not being anticonvulsant or myorelaxant".2 The PubMed record carries no funding statement, and only that record was read. No study of receptor binding by apigenin in people was identified in the PubMed query run for this compound. For the app's note on cortisol, the PubMed query "apigenin cortisol humans" returned four records, and none of their titles describes a human trial of apigenin.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~12 h
- Bioavailability
- 30%
- Typical dose
- 50–100 mg/day
- Route
- Oral
- Time to peak
- ~4 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~12 h | An excretion half-life "estimated to be approximately 12 hours" from a human parsley-feeding study described in a 2019 review, in which plasma concentrations were not measured3 |
| Bioavailability | 30% | Metabolites equal to 0.5% of intake in urine over 0 to 24 h after apigenin itself, 11.2% after a parsley drink and 34% after chamomile tea, in healthy men; these are urinary recoveries of metabolites, not a measured absolute bioavailability1 |
| Time to peak | ~4 h | Peak plasma concentration of the metabolite apigenin-4'-glucuronide at 4 h after a parsley drink, 6 h after dried parsley leaves with yogurt and 2 h after chamomile tea; the time for the apigenin capsule is not given in the record read1 |
| Route | Oral | Apigenin capsule mixed with 300 mL hot water in the registered absorption study4 |
Borges and colleagues (University of California, Davis, Free Radical Biology and Medicine, 2022) identified apigenin-4'-glucuronide, apigenin-7-glucuronide and apigenin-7-sulfate as in vivo metabolites.1 They describe the 4 h peak after the parsley drink as "indicative of absorption in the lower gastrointestinal tract" and the 2 h peak after chamomile tea as "in keeping with absorption in the upper GIT".1 The 2019 review states that "oral bioavailability of apigenin is poor; it is either excreted unabsorbed in the urine or feces or rapidly metabolized after absorption", and that "little is known about the bioavailability of flavones" compared with other flavonoid classes.3 In rats given radiolabeled apigenin by mouth, the same review reports that "the elimination half-time was high with a value of 91.8 hours"; this is an animal figure and is not the app's figure.3
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Borges and colleagues, Free Radical Biology and Medicine 20221 | Non-randomised crossover dietary study; University of California, Davis lead sponsor with Mars, Inc. as collaborator4 | Healthy men aged 25 to 60 at eligibility; 17 enrolled per the registry4 | Single intakes of an apigenin capsule, chamomile tea (300 mL) or parsley products; urine 0 to 24 h; capsule strength not given in the records read4,1 | Urinary metabolites equal to 0.5% of intake for apigenin itself, 11.2% for a parsley drink and 34% for chamomile tea1 |
| Janssen and colleagues, American Journal of Clinical Nutrition 19987 | Randomised crossover with placebo7 | 18 healthy volunteers7 | 5 g dried parsley a day providing 84 mg apigenin a day, 220 g onions a day, or placebo, 7 d each, with each treatment period also stated as lasting 2 wk7 | Plasma apigenin could not be measured; no significant effects of onions or parsley on platelet aggregation, thromboxane B2 production, factor VII or other hemostatic variables7 |
| Mastrofini and colleagues, Journal of the International Society of Sports Nutrition 20265 | Double-blind, placebo-controlled, four groups (morning product, evening product, both, placebo); funded by Momentous LLC5 | 103 healthy physically active adults finished (115 randomised); evening-product group n = 255 | Evening product: 2 g magnesium L-threonate, 200 mg L-theanine and 50 mg apigenin, with placebo in the morning; 2 weeks of supplementation in a 4-week study5 | Evening product condition (PM): no significant effect on perceived stress (p = 0.684); the evening-only group had an increase in wake after sleep onset after treatment week 2 (p = 0.009; d = 0.94); the authors call evening-only supplementation insufficient; the apigenin effect cannot be separated from the other two ingredients5 |
| Zick and colleagues, University of Michigan, BMC Complementary and Alternative Medicine 20116 | Randomised, double-blind, placebo-controlled pilot of a chamomile extract, not of apigenin alone6 | 34 adults aged 18-65 with DSM-IV primary insomnia for 6 months or more6 | Chamomile extract 270 mg twice daily or placebo for 28 days; the extract was analysed at 3.9 mg apigenin per 90 mg6 | No significant differences between groups in sleep diary measures; total sleep time had a moderate effect size in favor of placebo, while sleep latency (0.47 Cohen's d) and night time awakenings (0.61 Cohen's d) showed modest advantages for chamomile that did not reach significance6 |
Deeper analysis: the absorption study (Borges, 2022)
Borges and colleagues, University of California, Davis, tested single intakes of apigenin-containing materials in healthy men, and the registry entry lists five arms: chamomile tea, a parsley-based drink, parsley in yogurt, an apigenin capsule and a second parsley-based drink.4 The registry gives masking as single, with the investigator doing the data analysis masked, and the allocation as non-randomised.4 The registry's primary outcomes are flavone metabolites in plasma before to 6 h after intake and in urine from 12 h before to 24 h after intake.4 The authors report that apigenin "per se was poorly absorbed", that the parsley drink and chamomile tea gave urinary recoveries of 11.2% and 34% of intake, and that the 4 h and 2 h plasma peaks of apigenin-4'-glucuronide were "indicative of absorption in the lower gastrointestinal tract" and "in keeping with absorption in the upper GIT".1 The parsley drink was also used to describe variation, as "Intake of the parsley drink provided information on intra- and inter-individual variations in the level of excretion of the apigenin metabolites".1 The records read give no capsule strength, no per-arm number of participants and no adverse event data, and the registry shows no posted results.4 The registry lists University of California, Davis as lead sponsor and Mars, Inc. as a collaborator, names a Mars, Inc. study director, and one author lists a Mars Inc. affiliation.4,1 Only the PubMed record of the paper was read, so the authors' own statement of limitations is not reported here.
Deeper analysis: the evening supplement trial (Mastrofini, 2026)
Mastrofini and colleagues, University of South Carolina, reported a double-blind, placebo-controlled trial in the Journal of the International Society of Sports Nutrition in 2026.5 It randomised adults to a morning product (600 mg ashwagandha and 300 mg Rhodiola rosea), an evening product, both, or placebo.5 The evening product held 2 g magnesium L-threonate, 200 mg L-theanine and 50 mg apigenin, and the apigenin was "from grapefruit".5 Products were capsules, "with 5 capsules taken in the morning and evening", and the placebo was microcrystalline cellulose.5 Outcomes were questionnaires on stress, mood and sleep plus nightly sleep tracking with a wearable device.5 For the evening product condition (active in the evening-only and combined groups), the paper reports no significant effect on weekly perceived stress (p = 0.684) and no condition reaching significance for negative affect.5 For wake after sleep onset (WASO), the results section reports an increase in the evening-only group after treatment week 2 (p = 0.009; d = 0.94), while the discussion says evening supplementation "was associated with a decrease in WASO".5 The authors conclude that morning-only supplementation was sufficient for improvements "whereas evening-only supplementation was insufficient", and that adding the evening product "may not provide additional benefits for select sleep-related outcomes".5 Because the evening product combined three ingredients, none of these results can be read as the effect of apigenin alone.5 The authors state that "the multi-ingredient blend used in the present study has not previously been investigated".5 Their stated limitations include self-reported stress outcomes, missing data from the sleep device, and a short supplementation period.5 The paper also states that "Due to incomplete data capture by the SleepImage device, 11 participants were excluded from the analysis of objective sleep metrics".5 The work was supported by Momentous LLC, which also produced the finished products, and the authors report no potential conflict of interest; the registry lists the University of South Carolina as lead sponsor and Momentous as a collaborator.5,8
Deeper analysis: the chamomile extract pilot (Zick, 2011)
Zick and colleagues, with the registry naming the University of Michigan as sponsor, reported a pilot trial of a standardised chamomile extract in BMC Complementary and Alternative Medicine in 2011.6,9 The extract is not apigenin alone; each 90 mg of extract was analysed to contain 3.9 mg of apigenin and 1.8 mg of (-)-α-bisabolol.6 Of 107 people screened, 34 were randomised, 17 to placebo and 17 to chamomile, and no participant discontinued the intervention.6 The primary outcomes were sleep diary measures, and the authors report "no significant differences between groups" in them.6 Chamomile "did show modest advantage on daytime functioning, although these did not reach statistical significance", the discussion reports a modest benefit on sleep latency (0.47 Cohen's d) and night time awakenings (0.61 Cohen's d) that did not reach statistical significance, and total sleep time had a moderate effect size in favor of placebo.6 Among limitations, the authors list subjective sleep measures and "a small sample size of only 34 participants".6 They also note that "no studies have examined the pharmacokinetics or pharmacodynamics of chamomile".6 Funding came from a University of Michigan seed grant and an NIH-linked institute grant, the authors state the funders had no role in the study, MediHerb offered no financial support or drug, and the authors declare no competing interests.6
Parsley and platelet function (Janssen, 1998)
Janssen and colleagues, Department of Human Nutrition, Agricultural University, Wageningen, reported an in vitro experiment and a feeding study in the American Journal of Clinical Nutrition in 1998.7 In vitro, 2500 micromol/L of apigenin or quercetin inhibited collagen- and ADP-induced platelet aggregation by approximately 80-97%, while "lower concentrations, such as might occur in vivo, had no effect".7 In the 18-volunteer crossover, onions raised mean plasma quercetin to 1.5 micromol/L while "plasma apigenin could not be measured".7 The authors conclude that "the antiaggregatory effects of flavonoids seen in vitro are due to concentrations that cannot be attained in vivo".7 The PubMed record names no funder, and only that record was read.
Doses reported in studies and on labels
| Study | Material, dose and route | Comparator and length | People |
|---|---|---|---|
| Mastrofini 20265 | Evening product with 50 mg apigenin (from grapefruit), 2 g magnesium L-threonate and 200 mg L-theanine, oral capsules | Placebo capsules; 2 weeks of supplementation | n = 25 in the evening-only group5 |
| Zick 20116 | Chamomile extract 270 mg twice daily, analysed at 3.9 mg apigenin per 90 mg of extract, oral tablets | Matching placebo; 28 days | 34 randomised, 17 per group6 |
| Janssen 19987 | 5 g dried parsley a day providing 84 mg apigenin a day, oral dietary supplement | Placebo; 7 d each, with each treatment period also stated as lasting 2 wk | 18 healthy volunteers7 |
| Parsley-feeding study described in a 2019 review3 | Chopped parsley supplying approximately 51 mg of apigenin equivalent each day, mainly as apigenin-7-apioside, in the diet | Basic diet; 1 week | Not stated in the review text read |
| Borges 20221 | Apigenin capsule in 300 mL hot water, single intake; strength not given in the records read | Crossover with chamomile tea and parsley products; urine 0 to 24 h | 17 enrolled per the registry4 |
The app lists a typical dose of 50–100 mg/day. Among the studies read, 50 mg of apigenin appears in the evening product of Mastrofini and colleagues, and no study read lists 100 mg a day.5 The DailyMed query for apigenin returned no labels, so no label dose is available.
Side effects reported
In the chamomile extract pilot, the authors report "no significant differences in total adverse events (AE) between treatment groups", with all adverse events "mild (graded as a 1 on the NCI toxicity criteria) and transient".6 They state that "No serious adverse events were reported".6 The paper's text gives 10 adverse events in the placebo group and 6 in the other group (p = 0.30), while its Table 3 lists "Any AE" in 10 (58.8%) placebo and 6 (35.5%) chamomile participants with p = 0.03 by Fisher's exact test.6 In the evening-supplement trial, two male participants were withdrawn for possible study-related adverse events, and both were in the morning-product group, which did not contain apigenin.5 The paper adds that "No other potentially study-related adverse events were reported".5 One withdrawn participant reported mild gastrointestinal distress in the form of diarrhea after the third day and the other moderate dizziness and mild muscle weakness after two days, and symptoms resolved within 48 h of stopping; the participant flow also lists 3 discontinuations in the combined morning and evening group (international travel n = 1, issues with the sleep device n = 2).5 The 2019 review states that apigenin "is not mutagenic nor hemolytic" in Ames and hemolytic tests and "has not been reported to be harmful" when taken as glucosides in the diet.3 The same review adds that "as consumers intentionally increase apigenin intake from dietary supplements or pharmaceutical sources, safety concerns may arise with a higher level of apigenin exposure".3 The Borges absorption study records read give no adverse event data.4
Regulatory and anti-doping status
Sources in this part
A text search of the World Anti-Doping Agency's 2026 Prohibited List found no mention of apigenin.10 The list's S0 class covers any pharmacological substance "not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".10 The list text read does not say how that class applies to a supplement ingredient such as apigenin.10 The DailyMed query for apigenin returned no labels, and no FDA or EMA assessment of apigenin was identified in the queries run.
What is not known
Sources in this part
The sources read do not report a plasma half-life for apigenin itself in people; the 12 h figure is an excretion half-life estimated from a parsley study in which plasma was not measured.3 The capsule strength and per-arm results of the absorption study were not in the records read, so the 0.5% figure rests on a summary record.1 The only placebo-controlled sleep trial identified that included isolated apigenin as an ingredient tested a three-ingredient evening product in healthy adults for two weeks, and the authors call that blend previously uninvestigated.5 Whether apigenin lowers cortisol at night in people, as the app's notes state, was not established by any human study identified in the PubMed query run. The review notes that "safety concerns may arise with a higher level of apigenin exposure", and no long-term human safety study of apigenin was identified in the queries run.3
Frequently asked questions
What is the half-life of apigenin?
What is the bioavailability of apigenin?
How long does apigenin take to reach its peak level?
Is apigenin banned by WADA?
Is apigenin the same as chamomile?
Does apigenin bind GABA receptors?
In a 1995 laboratory and mouse study, apigenin "competitively inhibited the binding of flunitrazepam with a Ki of 4 microM" at the central benzodiazepine receptor.2 It "had no effect" on the binding of muscimol to GABAA receptors in that study, and no human receptor study was identified in the PubMed query run.2
Did apigenin improve sleep in a clinical trial?
In the only placebo-controlled sleep trial identified that included isolated apigenin as an ingredient, the evening product condition had no significant effect on perceived stress (p = 0.684) and the authors call evening-only supplementation insufficient.5 That product also contained magnesium L-threonate and L-theanine, so the result is not specific to apigenin.5
What side effects were reported in apigenin-related trials?
Guides, tools and comparisons
References
- Borges G, Fong RY, Ensunsa JL, Kimball J, Medici V, Ottaviani JI, Crozier A. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radic Biol Med 2022;185:90-96. PMID 35452808
- Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 1995;61(3):213-216. PMID 7617761
- Wang M, Firrman J, Liu L, Yam K. A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota. Biomed Res Int 2019. PMC6817918
- University of California, Davis. Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides. ClinicalTrials.gov NCT03526081. NCT03526081
- Mastrofini GF, Romersi RF, Lombardi MG, Persaud KT, Ryan MM, Hirsch KR, Fraley AL, Dawes JJ, Stray-Gundersen SO, Hardin JW, Arent SM. Modulating stress and sleep through a multi-compound dietary supplement: a randomized, double-blind, placebo-controlled trial. J Int Soc Sports Nutr 2026;23(1):2740227. PMC13644447
- Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med 2011;11:78. PMC3198755
- Janssen K, Mensink RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC, Katan MB. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998;67(2):255-262. PMID 9459373
- University of South Carolina. Supplement Combination on Stress and Sleep. ClinicalTrials.gov NCT06889584. NCT06889584
- University of Michigan. Chamomile for Chronic Primary Insomnia. ClinicalTrials.gov NCT01286324. NCT01286324
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list